Showing results (81-90 of 136) with videos related to

Sort By:
Pageof 14
Hematological Oncology|July 21, 2019
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD NetworkIrene Della Starza, Marzia Cavalli, Lucia Anna De Novi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 7, 2018
Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple MyelomaLaurent Garderet, Simona Iacobelli, Linda Koster, et al.
Thrombosis and Haemostasis|April 28, 2017
Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL)Roberto Mario Santi, Manuela Ceccarelli, Elisa Bernocco, et al.
Blood|November 26, 2015
Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomasBiljana Culjkovic-Kraljacic, Tharu M Fernando, Rossella Marullo, et al.
British Journal of Haematology|January 24, 2014
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patientsAlberto Rocci, Manuela Gambella, Simona Aschero, et al.
Hematological Oncology|March 20, 2021
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphomaElisa Genuardi, Petra Klous, Barbara Mantoan, et al.
Haematologica|December 31, 2011
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genesSimone Ferrero, Daniela Capello, Mirija Svaldi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2016
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized TrialsQian Shi, Christopher R Flowers, Wolfgang Hiddemann, et al.
Bone Marrow Transplantation|April 25, 2024
Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC)Christian Niederwieser, Simona Iacobelli, Georg-Nikolaus Franke, et al.
Blood Advances|August 5, 2025
Outcomes of CAR T-cells therapy in High-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysisAnna Dodero, Giusy Ceparano, Beatrice Casadei, et al.
Pageof 14